Dateline City:
KENILWORTH, N.J.
Findings Presented at the 57th American Society of Hematology Annual Meeting Demonstrate Activity of KEYTRUDA Therapy in Previously-Treated Multiple Myeloma Patients When Combined with Lenalidomide and Dexamethasone
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today new study findings investigating the use of KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, in combination with
lenalidomide and low-dose dexamethasone (two commonly used treatments
for multiple myeloma) in patients whose disease has progressed after at
least two lines of prior therapy, including a proteasome inhibitor and
an IMiD (immune modulatory drug).
Language:
English
Contact:
Media:Pamela Eisele, 267-305-3558orKim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more